J&J revenue misses on lower-than-expected pharmaceutical sales
[BENGALURU] Johnson & Johnson, which is in the process of completing its US$30 billion acquisition of Swiss biotech Actelion, reported on Tuesday quarterly revenue that missed analysts' estimates, hurt by lower demand for its pharmaceutical products.
The diversified healthcare company's sales rose to US$17.77 billion in the first quarter from US$17.48 billion a year earlier, but came in below analysts' average estimate of US$18.04 billion, according to Thomson Reuters I/B/E/S.
Pharmaceutical sales rose 0.8 per cent to US$8.25 billion, below Barclays estimate of US$8.47 billion.
Net earnings in the quarter were US$4.42 billion, or US$1.61 per share, compared with US$4.46 billion, or US$1.59 per share, in the year-earlier period.
Excluding items, the company earned US$1.83 per share, beating Street expectations of US$1.77 per share.
J&J is the first among major pharmaceutical companies to report quarterly results, a month after the Republican attempt to overhaul the US healthcare system spectacularly failed, although a renewed effort is said to be in the works.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices